Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.76 |
| ▸ | PDE4A | P27815 | 3/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.59 |
| ▸ | F2 | P00734 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6109820 | 0.88 | F10 (0.70) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1994271 | 0.87 | F10 (0.70) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5644187 | 0.86 | F10 (1.00) | F10F2 | |
| SCHEMBL5644520 | 0.86 | F10 (0.67) | F10 | |
| SCHEMBL5646893 | 0.85 | F10 (0.83) | F10F2 | |
| SCHEMBL1999802 | 0.85 | PDE4A (0.66) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4593475 | 0.84 | F10 (0.66) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1994126 | 0.84 | F10 (0.66) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4593373 | 0.84 | F10 (0.66) | F10PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5644575 | 0.84 | F10 (1.00) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-07 | — | — | US | disclosed |
| CN-110894196-A | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | 百时美-施贵宝控股爱尔兰无限公司 | 2020-03-20 | — | — | CN | disclosed |
| US-20180244673-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-30 | — | — | US | disclosed |
| US-9975891-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170050964-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-02-23 | — | — | US | disclosed |
| US-20150210691-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-30 | — | — | US | disclosed |
| US-20140113892-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-24 | — | — | US | disclosed |
| US-8470854-B2 | Lactam-containing compounds and derivatives thereof as factor XA inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120201816-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-09 | — | — | US | disclosed |
| US-8188120-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20050267097-A1 | blood coagulation factor (trypsin-like serine protease enzymes) inhibitor; 3-(4-methoxy-phenyl)-5-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3,5,6,7-tetrahydro-[1,2,3]triazolo4,5-c]pyridin-4-one; anticoagulant; cardiovascular thromboembolic disorder transient ischemic attack, stroke, atherosclerosis | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
| US-20050261287-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | disclosed |
| US-6967208-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| US-6949550-B2 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050171085-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-04 | — | — | US | disclosed |
| US-20050124602-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-09 | — | — | US | disclosed |
| US-6750225-B2 | ANTICOAGULANTS | BRISTOL-MYERS SQUIBB PHARMS COMPANY | 2004-06-15 | — | — | US | disclosed |
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-13 | — | — | US | disclosed |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-09 | — | — | US | disclosed |
| US-20020177713-A1 | 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244673-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | F10 45/4885PDE4A 1122/4885PDE4B 1340/4885 |
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | F11, F10, F9 | F10 2/4885PDE4A 1745/4885PDE4B 1971/4885 |
| US-20120201816-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | F10 45/4885PDE4A 1122/4885PDE4B 1340/4885 |
| US-20020177713-A1 | 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors | SERPINC1, SERPINE1, F11 | F10 31/4885PDE4A 2491/4885PDE4B 2144/4885 |
| US-20150210691-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | F10 43/4885PDE4A 1241/4885PDE4B 1454/4885 |
| US-20050261287-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | F12, F2, CPB1 | F10 45/4885PDE4A 1122/4885PDE4B 1340/4885 |
| US-20170050964-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | F10 45/4885PDE4A 1122/4885PDE4B 1340/4885 |
| US-20050124602-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | F12, F2, CPB1 | F10 43/4885PDE4A 1241/4885PDE4B 1454/4885 |
| US-20050267097-A1 | blood coagulation factor (trypsin-like serine protease enzymes) inhibitor; 3-(4-methoxy-phenyl)-5-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3,5,6,7-tetrahydro-[1,2,3]triazolo4,5-c]pyridin-4-one; anticoagulant; cardiovascular thromboembolic disorder transient ischemic attack, stroke, atherosclerosis | PLAT, F2, TFPI | F10 62/4885PDE4A 2706/4885PDE4B 3116/4885 |
| US-20050171085-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | F12, F2, CPB1 | F10 45/4885PDE4A 1122/4885PDE4B 1340/4885 |
| US-20140113892-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | F10 43/4885PDE4A 1241/4885PDE4B 1454/4885 |
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | F10 43/4885PDE4A 1241/4885PDE4B 1454/4885 |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | PEPD, HABP2, CPB1 | F10 33/4885PDE4A 1937/4885PDE4B 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.